Erythropoietin and epidemiology of alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 27, Issue 3, 2013, Pages 204-206

  Ismailov, Rovshan M ^a  

^a NATIONAL UNIVERSITY OF UZBEKISTAN   (Uzbekistan)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN;

ALTITUDE; ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; HOSPITAL DISCHARGE; HUMAN; ICD-9-CM; PRIORITY JOURNAL; RANDOM SAMPLE; UNITED STATES; BLOOD;

ALZHEIMER DISEASE; ERYTHROPOIETIN; HUMANS;

EID: 84883292890     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e31827b61b8     Document Type: Article

References (15)

1. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12:383-388.
2. Davis DG, Schmitt FA, Wekstein DR, et al. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999;58:376-388.
3. de la Torre JC. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease. Ann N Y Acad Sci. 2000;924:136-152.
4. Ismailov RM. New insights into the mechanism of Alzheimer's disease: a multidisciplinary approach [Book online]. Amazon Kindle Press; 2010. Available at http://www.amazon.com/Insights-Mechanisms-Alzheimers-Disease-ebook/dp/ B0045JLQFK. Accessed October 9, 2012.
5. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141:14-31.
6. Ismailov RM. The role of erythropoietin in the "stroke belt" phenomenon. Med Hypotheses. 2012;79:181-185.
7. Infoplease. Highest, Lowest, and Mean Elevations in the United States. 2012 [cited 2012 02/05]. Available at: http://www.info please.com/ipa/A0001792. html. Accessed October 9, 2012.
8. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature. 2001;412:641-647.
9. Lee ST, Chu K, Sinn DI, et al. Erythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhage. J Neurochem. 2006;96:1728-1739.
10. Swanson RA, Ying W, Kauppinen TM. Astrocyte influences on ischemic neuronal death. Curr Mol Med. 2004;4:193-205.
11. Takuma K, Yoshida T, Lee E, et al. CV-2619 protects cultured astrocytes against reperfusion injury via nerve growth factor production. Eur J Pharmacol. 2000;406:333-339.
12. Ehrenreich H, Hinze-Selch D, Stawicki S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry. 2007;12:206-220.
13. Chong ZZ, Kang JQ, Maiese K. Angiogenesis and plasticity: role of erythropoietin in vascular systems. J Hematother Stem Cell Res. 2002;11:863-871.
14. Nakano M, Satoh K, Fukumoto Y, et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res. 2007;100:662-669.
15. Eckardt KU, Boutellier U, Kurtz A, et al. Rate of erythropoietin formation in humans in response to acute hypobaric hypoxia. J Appl Physiol. 1989;66:1785-1788.